Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model

Journal of Pediatric Hematology/Oncology

Volumn 19, Issue 6, 1997, Pages 536-540

  Dunussi Joannopoulos, Kyriaki ^a   Weinstein, Howard J ^a   Arceci, Robert J ^b   Croop, James M ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

AML; B7; Gene therapy; GM CSF; Murine models

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; GENE THERAPY; HEMATOPOIETIC CELL; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTIGENS, CD80; CANCER VACCINES; DISEASE MODELS, ANIMAL; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; LEUKEMIA, MYELOCYTIC, ACUTE; MICE;

EID: 0031424377     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199711000-00012     Document Type: Article

References (27)

1. Burnett AK, Eden OB. The treatment of acute leukemia. Lancet 1997;349:270-5.
2. Chen L, Linsley PS, Hellström KE. Costimulation of T cells for tumor immunity. Immunol Today 1993;14:483-6.
3. Powis SJ, Townsend ARM, Deverson EV, Bastin J, Butcher GW, Howard JC. Restoration of antigen presentation of the mutant cell line RMA-S by an MHC-linked transporter. Nature 1991;354:528-31.
4. Germain RN, Margulies DH. The biochemistry and cell biology of antigen presentation. Annu Rev Immunol 1993;11:403-50.
5. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995;13:399-415.
6. Weaver CT, Unanue ER. The costimulatory function of antigen-presenting cells. Immunol Today 1990;11:49-55.
7. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990;248:1349-56.
8. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994;15:321-31.
9. Hellström KE. Hellström I, Chen L. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev 1995;145:123-45.
10. Chen L, Ashe S, Brady WA. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
11. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368-70.
12. Gansbacher B, Zier K, Daniels B, et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
13. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503-12.
14. Sun WH, Kreisle RA, Philips AW, et al. In vivo and in vitro characteristics of interleukin 6-transfected B16 melanoma cells. Cancer Res 1992;52:5412-5.
15. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented antitumor immunity. Proc Natl Acad Sci USA 1989;86:9456-60.
16. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
17. Levitsky HI, Montgomery J, Ahmadzadeh M, et al. Immunization with GM-CSF-transduced, but not B7-1-transduced lymphoma cells primes idiotype-specific T cells and generates potent anti-tumor immunity. J Immunol 1996;3858-65.
18. Dranoff G, Mulligan RC. Gene transfer as cancer therapy. Adv Immunol 1995;58:417-54.
19. Dunussi-Joannopoulos K, Weinstein HJ, Nickerson PW, et al. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 1996;87:2938-46.
20. Dunussi-Joannopoulos K, Dranoff G, Weinstein HJ, et al. Gene therapy in murine AML: GM-CSF tumor cell vaccines elicit more potent antitumor immunity compared to B7 family and other cytokine vaccines. Blood (in press).
21. Resnitzky P, Estrov Z, Haran-Ghera N. High incidence of acute myeloid leukemia in SLJ/J mice after x-irradiation and corticosteroids. Leukemia Res 1985;9:1519-28.
22. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more, Immunol Today 1996;17:138-46.
23. Seder RA, Paul WE. Acquisition of lymphocyte-producing phenotype by CD4+ T cells. Ann Rev Immunol 1994;12:635-73.
24. Schoof DD, Terashima Y, Peoples GE, et al. CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. Cell Immunol 1993;150:114-23.
25. Ghosh P, Komschiles KL, Cippitelli M, et al. Gradual loss of T-helper 1 population in spleen of mice during progressive tumor growth. J Natl Cancer Inst 1995;87:1478-83.
26. Dunussi-Joannopoulos K, Krenger W, Weinstein HJ, et al. CD8+ T-cells activated during the course of murine AML elicit therapeutic responses to late B7 vaccines after cytoreductive treatment. Blood 1997;89:2915-24.
27. Kersh GJ, Allen PM. Essential flexibility in the T-cell recognition of antigen. Nature 1996;380:495-8.